Comparative Pharmacology
Head-to-head clinical analysis: LEVO T versus UNITHROID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVO T versus UNITHROID.
LEVO-T vs UNITHROID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levothyroxine is a synthetic form of thyroxine (T4), a thyroid hormone. It is deiodinated to triiodothyronine (T3), which binds to nuclear thyroid hormone receptors, resulting in modulation of gene transcription and increased metabolic rate.
Synthetic T4 (levothyroxine) is converted to T3, which binds to thyroid hormone receptors to regulate gene transcription, increasing basal metabolic rate.
1.6 mcg/kg orally once daily (typical adult starting dose 50-100 mcg/day); adjust by 12.5-25 mcg increments every 4-6 weeks based on TSH.
Initial adult dose: 25-50 mcg orally once daily; titrate by 12.5-25 mcg every 4-6 weeks based on TSH; typical maintenance: 75-150 mcg orally once daily; maximum dose up to 300 mcg daily in severe hypothyroidism.
None Documented
None Documented
Terminal elimination half-life is approximately 6-7 days in euthyroid individuals; in hyperthyroidism, half-life shortens to 3-4 days; in hypothyroidism, it prolongs to 9-10 days. The long half-life supports once-daily dosing.
6-7 days for L-thyroxine (T4) in euthyroid patients; prolonged to 9-10 days in hypothyroidism, shortened to 3-4 days in hyperthyroidism. Clinical context: once-daily dosing achieves steady state in 6-8 weeks.
Renal: ~20-40% of administered levothyroxine is excreted in urine as unchanged drug and conjugates; biliary/fecal: ~40-60% is excreted in feces via bile, largely as conjugates and minor amounts of unchanged drug.
Renal (approx. 20-40% as unchanged drug and glucuronide conjugates); fecal (minor, via bile).
Category C
Category C
Thyroid Hormone
Thyroid Hormone